Fefer Paul, Hod Hanoch, Matetzky Shlomi
Heart Institute, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel Aviv University, Israel.
Platelets. 2007 May;18(3):175-81. doi: 10.1080/09537100601039747.
Platelet activation and aggregation play a major role in the pathogenesis of acute coronary syndromes. While clopidogrel has convincingly been shown to reduce atherothrombotic events in patients with acute coronary syndromes, and following percutaneous coronary interventions (PCI), a significant portion of patients continue to suffer cardiovascular events. A growing body of literature suggests that at least part of this treatment failure can be attributed to resistance to anti-thrombotic treatment in these patients. The purpose of this review is to clarify the current knowledge regarding clopidogrel resistance.
血小板活化和聚集在急性冠状动脉综合征的发病机制中起主要作用。虽然氯吡格雷已被确凿地证明可减少急性冠状动脉综合征患者以及经皮冠状动脉介入治疗（PCI）后的动脉粥样硬化血栓形成事件，但仍有相当一部分患者继续发生心血管事件。越来越多的文献表明，这种治疗失败至少部分可归因于这些患者对抗血栓治疗的抵抗。本综述的目的是阐明关于氯吡格雷抵抗的现有知识。
